Gastric Ulcers - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gastric Ulcers - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gastric Ulcers - Pipeline Review, H2 2014', provides an overview of the Gastric Ulcers's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastric Ulcers and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastric Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastric Ulcers Overview 6
Therapeutics Development 7
Pipeline Products for Gastric Ulcers - Overview 7
Pipeline Products for Gastric Ulcers - Comparative Analysis 8
Gastric Ulcers - Therapeutics under Development by Companies 9
Gastric Ulcers - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Gastric Ulcers - Products under Development by Companies 13
Gastric Ulcers - Companies Involved in Therapeutics Development 14
Astellas Pharma Inc. 14
ChoDang Pharm Co., Ltd. 15
Daewoong Pharmaceutical Co., Ltd. 16
Priaxon AG 17
Sihuan Pharmaceutical Holdings Group Ltd. 18
Takeda Pharmaceutical Company Limited 19
Gastric Ulcers - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 27
300-PXN-0040 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
anaprazole sodium - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ASP-6537 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DWJ-206 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PMKS-005 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules for Gastric Ulcers - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
vonoprazan - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gastric Ulcers - Recent Pipeline Updates 36
Gastric Ulcers - Dormant Projects 37
Gastric Ulcers - Discontinued Products 38
Gastric Ulcers - Product Development Milestones 39
Featured News & Press Releases 39
May 07, 2014: Presentation of Highlight Results from recent Phase 3 Trials of Vonoprazan Fumarate for the Treatment of Acid-related Diseases at the DDW 2014 Meeting 39
Feb 28, 2014: Takeda Submits a New Drug Application for TAK-438 in Japan for the Treatment of Acid-related Diseases 39
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 40
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases 41
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases 41
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 41
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 42
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 42
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 43
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Gastric Ulcers, H2 2014 7
Number of Products under Development for Gastric Ulcers - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Gastric Ulcers - Pipeline by Astellas Pharma Inc., H2 2014 14
Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H2 2014 15
Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 16
Gastric Ulcers - Pipeline by Priaxon AG, H2 2014 17
Gastric Ulcers - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2014 18
Gastric Ulcers - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 26
Gastric Ulcers Therapeutics - Recent Pipeline Updates, H2 2014 36
Gastric Ulcers - Dormant Projects, H2 2014 37
Gastric Ulcers - Discontinued Products, H2 2014 38